Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 67.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 88,729 shares of the biotechnology company's stock after selling 187,664 shares during the period. SG Americas Securities LLC's holdings in Iovance Biotherapeutics were worth $721,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of IOVA. Kennedy Capital Management LLC raised its position in shares of Iovance Biotherapeutics by 52.3% in the 3rd quarter. Kennedy Capital Management LLC now owns 344,042 shares of the biotechnology company's stock worth $1,565,000 after acquiring an additional 118,133 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Iovance Biotherapeutics by 41.3% in the 3rd quarter. Principal Financial Group Inc. now owns 2,643,155 shares of the biotechnology company's stock worth $12,026,000 after acquiring an additional 772,905 shares in the last quarter. Artisan Partners Limited Partnership raised its position in shares of Iovance Biotherapeutics by 13.8% in the 3rd quarter. Artisan Partners Limited Partnership now owns 5,036,479 shares of the biotechnology company's stock worth $22,916,000 after acquiring an additional 609,738 shares in the last quarter. Mariner LLC raised its position in shares of Iovance Biotherapeutics by 107.3% in the 3rd quarter. Mariner LLC now owns 371,850 shares of the biotechnology company's stock worth $1,692,000 after acquiring an additional 192,450 shares in the last quarter. Finally, Banque Pictet & Cie SA raised its position in shares of Iovance Biotherapeutics by 18.7% in the 3rd quarter. Banque Pictet & Cie SA now owns 633,794 shares of the biotechnology company's stock worth $2,884,000 after acquiring an additional 99,636 shares in the last quarter. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Stock Up 1.7 %

Iovance Biotherapeutics stock traded up $0.24 during trading on Wednesday, hitting $14.01. The stock had a trading volume of 4,554,351 shares, compared to its average volume of 9,561,162. Iovance Biotherapeutics, Inc. has a 1 year low of $3.21 and a 1 year high of $18.33. The stock's 50 day moving average is $12.69 and its two-hundred day moving average is $8.25. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of -7.32 and a beta of 0.62.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $1.44 million. During the same quarter last year, the firm posted ($0.64) EPS. As a group, equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insider Buying and Selling at Iovance Biotherapeutics

In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the stock in a transaction on Tuesday, February 20th. The shares were acquired at an average price of $9.15 per share, with a total value of $2,287,500.00. Following the acquisition, the director now directly owns 320,150 shares of the company's stock, valued at approximately $2,929,372.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 10.40% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IOVA. Barclays boosted their target price on Iovance Biotherapeutics from $18.00 to $22.00 and gave the company an "overweight" rating in a research report on Thursday, February 29th. StockNews.com raised Iovance Biotherapeutics to a "sell" rating in a research report on Friday, February 2nd. Chardan Capital boosted their target price on Iovance Biotherapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research report on Tuesday, February 20th. Wells Fargo & Company boosted their target price on Iovance Biotherapeutics from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, March 1st. Finally, JMP Securities boosted their target price on Iovance Biotherapeutics from $18.00 to $25.00 and gave the company a "market outperform" rating in a research report on Tuesday, February 20th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.64.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.